These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 15504286)

  • 1. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
    Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
    Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
    Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
    J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
    Ooga H; Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1078-84. PubMed ID: 15580401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lamivudine treatment of patients with decompensated HBV cirrhosis and mutation in YMDD motif].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):77-8. PubMed ID: 15670511
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
    Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
    Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].
    Kim SS; Chung MG; Ju KT; Park DK; Kwon OS; Koo YS; Kim YK; Choi DJ; Hwang YJ; Kim JH
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):405-17. PubMed ID: 12506245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.